Merck pens mega licensing deal with Kelun-Biotech

22 December 2022
kelun_biotech_large

While the vast majority of M&A deals announced so far this year are in the hundreds of million dollars, licensing agreements have been getting ever bigger.

Just last week, Takeda (TYO: 4502) punted a record upfront of $4 billion, plus $2 billion in milestone, on an accord with Nimbus; today US pharma giant Merck & Co (NYSE: MRK) is going even further.

Merck says it has entered into an exclusive license and collaboration agreement with Kelun-Biotech, a holding subsidiary of Sichuan Kelun Pharmaceutical (SHE: 002422), to develop seven investigational pre-clinical antibody-drug conjugates (ADC) for the treatment of cancer. Sichuan Kelun shares dipped nearly 2% on the news

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology